INTENSITY THERAPEUTICS, INC.
INTENSITY THERAPEUTICS, INC. (INTS): 3 pipeline candidates · 2 upcoming catalysts · ~17 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
17.2 months
D/E 0.23 · 0% dilution
Lead: Phase 3
3 candidates
2 upcoming, next in ~204d
N/A
A transparent, data-derived signal for INTENSITY THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$10.3M
Cash
$10.2M
Quarterly Burn
$1.8M
Runway
17.2 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (3 candidates)
Upcoming Catalysts (2)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
11
Total value held
$846K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 33,682 | $198K |
| geode capital management, llc | 26,019 | $153K |
| sapient capital llc | 26,006 | $153K |
| nano cap new millennium growth fund l p | 25,000 | $147K |
| rothschild wealth llc | 23,294 | $137K |
| vanguard fiduciary trust co | 9,121 | $54K |
| osaic holdings, inc. | 200 | $1K |
| wells fargo & company/mn | 200 | $1K |
| ubs group ag | 192 | $1K |
| tower research capital llc (trc) | 67 | $394 |
Showing top 10 of 11 institutional holders of INTENSITY THERAPEUTICS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in INTENSITY THERAPEUTICS, INC.'s pipeline?
INTENSITY THERAPEUTICS, INC. (INTS) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is INTENSITY THERAPEUTICS, INC.'s lead drug candidate?
INTENSITY THERAPEUTICS, INC.'s most advanced tracked candidate is eribulin (Phase 3) for Sarcoma,Soft Tissue.
What is INTENSITY THERAPEUTICS, INC.'s next catalyst?
INTENSITY THERAPEUTICS, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: HALAVEN" — expected January 8, 2027.
What is INTENSITY THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, INTENSITY THERAPEUTICS, INC. has approximately 17.2 months of cash runway.
What is INTENSITY THERAPEUTICS, INC.'s market capitalization?
INTENSITY THERAPEUTICS, INC.'s market capitalization is approximately $10.3M.
Get the full picture on INTENSITY THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.